Importantly, we found that the elevated expression of PRMT5 was significantly correlated poor survival outcome of cervical cancer patients, and the PRMT5 inhibitor therapy was effective in a tumor-bearing mouse model of cervical cancer. The gene discussed is PRMT5; the disease is cervical carcinoma.